Quantum Biopharma Ltd QNTM

$1.61 -0.17 (-9.55%)

Valuation

Market cap
14,396,000
Revenue TTM
$0
Net income TTM
$-26,180,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
87,300
Avg volume
159,084
Day's range
$1.60 – $1.77
Shares out
8,087,000
Stochastic %K
1%
Beta
0.51
Analysts
Strong Buy
Price target
$21.75

Price

Company profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of de...

Show more

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
833-304-0323
Website
https://www.quantumbiopharma.com
Address
1 Adelaide Street East, Suite 801, Toronto, Canada

Latest news

Stocktwits

NetworkNewsWire Nov 13, 7:37 PM
InvestorNewsBreaks – $QNTM Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial https://ibn.fm/phOJG
0 replies
XQuise Nov 13, 5:32 PM
$QNTM 👀🎰🤏🏻
0 replies
ZacksResearch Nov 13, 4:00 PM
$QNTM’s financial position is strengthening — and its Phase 2 MS trial is moving forward! 🚀 💰 Cash + digital assets reach US$12.22M, up from US$4.12M at year-end 2025 📈 Shareholders’ equity jumps 91% to US$9.77M 📉 Operating expenses fall 32% over the first nine months of 2026 🧬 FDA clearance secured, with Thermo Fisher Scientific signing on to support Lucid-MS Phase 2 trial implementation ✅ Management says available cash and digital assets are sufficient for planned operations over the next twelve months. Stock down 👀 Can QNTM turn its improving balance sheet and clinical progress into momentum? See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-40110&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_40110
1 replies
FickleFin Nov 13, 3:52 PM
$GNS $QNTM 11/13/26 another one... REVERSE SPLIT. Dang these guys are giving investors the 🖕!!!
0 replies
FickleFin Nov 13, 2:13 PM
$QNTM $GNS $GME exit liquidity.
0 replies
Merlintrader Nov 13, 12:47 PM
$QNTM Quantum BioPharma, Nov 12: nine-month net loss of 17.3 million dollars (23.3 million a year ago), a Q3 loss of 0.47 million and cash of 3.56 million at Sept 30. Not investment advice. Catalysts, financials and the latest filings in our $QNTM stock hub: https://www.merlintrader.com/quantum-biopharma-stock-hub/
1 replies
FickleFin Nov 13, 11:37 AM
$QNTM $GNS short to zero. They led everyone to the slaughterhouse. Malone acted like the next roaring kitty... fucktard $GME
1 replies
FickleFin Nov 13, 11:34 AM
$QNTM $GNS GAME OVER. 🖕🤡🖕
0 replies